Monitor the outcome of the director election and auditor ratification as standard governance items. The non-binding vote on executive compensation provides insight into shareholder sentiment but does not mandate any financial changes.
Price Chart
Executive Summary
Corvus Pharmaceuticals filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting, which includes proposals to elect two Class I Directors, ratify the selection of PricewaterhouseCoopers LLP as the independent auditor, and approve the compensation of named executive officers. This filing follows the recent appointment of Dr. Andrew Chan to the board and the resignation of Scott Morrison, indicating board changes near the proxy materials. The vote is non-binding on executive compensation.
Key Facts
- The proxy statement is for the 2026 Annual Meeting of Stockholders, scheduled for June 11, 2026.
- Proposals include the election of two Class I Directors, ratification of PricewaterhouseCoopers LLP as the independent auditor, and approval of named executive officer compensation.
- The board recommends a vote FOR all proposals.
- This filing follows an 8-K filing on April 23, 2026, which announced the appointment of Dr. Andrew Chan to the board and the resignation of Scott Morrison.
- The vote on executive compensation is non-binding.
Financial Impact
No direct financial impact from the vote itself. The ratification of the auditor and director elections are standard governance actions. The compensation approval is non-binding.
Risk Factors
- Failure to ratify the auditor could lead to a restatement or audit issues.
- A significant vote against executive compensation could signal shareholder dissatisfaction, potentially impacting executive retention or company reputation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001104659-26-048600 |
| Document: 0001104659-26-048600-index-headers.html | 0001104659-26-048600 |
| Document: 0001104659-26-048600-index.html | 0001104659-26-048600 |
| Document: 0001104659-26-048600.txt | 0001104659-26-048600 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 6w ago | Institutional Cluster | $14.46 $12.42 | ▼ −14.11% | ▼ −13.58% | $10.90 (−24.62%) |
Jul 22, 2026 10w ago | 8-K | $13.68 $14.33 | ▲ +4.75% | ▲ +1.44% | $10.90 (−20.32%) |
Jun 11, 2026 16w ago | Institutional Cluster | $11.60 $16.20 | ▲ +39.66% | ▲ +37.76% | $10.90 (−6.03%) |
May 14, 2026 20w ago | 8-K | $13.66 $11.93 | ▼ −12.63% | ▼ −11.77% | $10.90 (−20.18%) |
May 7, 2026 21w ago | 8-K | $15.55 $11.12 | ▼ −28.49% | ▼ −28.51% | $10.90 (−29.90%) |
Apr 24, 2026 23w ago | DEFA14A | $15.92 $12.83 | ▼ −19.41% | ▼ −24.37% | $10.90 (−31.53%) |
Apr 21, 2026 23w ago | Press Release | $17.14 $12.21 | ▼ −28.76% | ▼ −33.68% | $10.90 (−36.41%) |
Mar 12, 2026 29w ago | Press Release | $15.32 $15.17 | ▼ −0.98% | ▼ −4.57% | $10.90 (−28.85%) |
Mar 5, 2026 30w ago | Press Release | $15.80 $14.71 | ▼ −6.87% | ▼ −4.82% | $10.90 (−30.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access